Reader TTS

Although imatinib mesylate therapy has dramatically improved the prognosis of patients in the advanced phases of chronic myeloid leukemia, room for improvement remains. Tyrosine kinase

inhibitors are undergoing evaluation as second-line therapy for patients with imatinib-resistant disease. Kantarjian _ et al_. recently demonstrated that once-daily dasatinib 140 mg is well

tolerated and achieves a high response rate. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access

through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink *

Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional

subscriptions * Read our FAQs * Contact customer support REFERENCES * Talpaz, M. _ et al_. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase:

results of a phase 2 study. _Blood_ 99, 1928–1937 (2002). Article  CAS  Google Scholar  * Talpaz, M. _ et al_. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemia. _N.

Engl. J. Med._ 354, 2531–2541 (2006). Article  CAS  Google Scholar  * Kantarjian, H. _ et al_. Phase 3 study of dasatinib 140 mg once daily versus twice daily in patients with chronic

myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15 months median follow-up. _Blood_ 113, 6322–6329 (2009). Article  CAS  Google Scholar  * Guilhot, F. _ et al_.

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. _Blood_ 109, 4143–4150

(2007). Article  CAS  Google Scholar  * Hochhaus, A. _ et al_. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of

imatinib therapy. _Blood_ 109, 2303–2309 (2006). Article  Google Scholar  * Cortes, J. _ et al_. Dasatinib induces complete hematologic and cytogenetic responses in patients with

imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. _Blood_ 109, 3207–3213 (2006). Article  Google Scholar  * Alfonso Quintás-Cardama, A. _ et al_. Pleural effusion in

patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. _J. Clin. Oncol._ 25, 3908–3914 (2007). Article  Google Scholar  * Le Coutre, P. _ et al_.

Nilotinib (formerly AMN 107), a highly selective BCR-ABL tyrosine kinase inhibitor, is a active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous

leukemia. _Blood_ 111, 1834–1839 (2008). Article  CAS  Google Scholar  * Shah, N. P. _ et al_. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improved

tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. _J. Clin. Oncol._ 26, 3204–3212 (2008). Article  CAS  Google Scholar  Download references AUTHOR

INFORMATION AUTHORS AND AFFILIATIONS * Departments of Oncology, Hematology, and Cell Therapy, Bone Marrow Transplant Unit, Centre Hospitalier Universitaire de Poitiers, France François

Guilhot & Lydia Roy Authors * François Guilhot View author publications You can also search for this author inPubMed Google Scholar * Lydia Roy View author publications You can also

search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to François Guilhot. ETHICS DECLARATIONS COMPETING INTERESTS F. Guilhot is a Consultant, on the Speakers

bureau, and receives grant/research support from Bristol-Myers Squibb and Novartis. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Guilhot, F., Roy, L.

Dasatinib regimens for patients with chronic myeloid leukemia. _Nat Rev Clin Oncol_ 6, 680–682 (2009). https://doi.org/10.1038/nrclinonc.2009.160 Download citation * Issue Date: December

2009 * DOI: https://doi.org/10.1038/nrclinonc.2009.160 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable

link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative